EchoGo Pro vs EchoNext
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 75/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
EchoGo Pro and EchoNext are adjacent competitors in the cardiology AI space, both FDA-cleared and aiming to improve cardiac diagnosis. EchoGo Pro focuses on automating stress echocardiography analysis for coronary artery disease detection, providing near-instant reports. EchoNext, on the other hand, analyzes standard ECGs to detect a broader range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, acting as a screening tool to identify patients who may need further echocardiogram testing.
Choose EchoGo Pro if…
Choose EchoGo Pro if your cardiology department requires an AI-powered, cloud-based solution for automated stress echocardiography analysis, specifically to improve the diagnosis of coronary artery disease (CAD). It is ideal for practices seeking near-instant, accurate reports and seamless integration with existing PACS, aiming to enhance diagnostic accuracy and reduce misdiagnosis in CAD assessment.
View EchoGo Pro →Choose EchoNext if…
Choose EchoNext if your practice needs an accessible, non-invasive AI tool to screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs. It is well-suited for broad implementation, from major hospitals to community practices, to identify at-risk patients who may require further echocardiogram evaluation.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | EchoGo Pro | EchoNext |
|---|---|---|
| Pricing | Contact vendor for pricing | Starts at $600/month |
| Deployment | Cloud-based (SaaS) | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | EchoGo Pro | EchoNext |
|---|---|---|
| Name | EchoGo Pro | EchoNext |
| Company | Ultromics | Pathway Labs |
| Description | EchoGo Pro is an FDA-cleared, AI-powered cloud solution by Ultromics that automates stress echocardiography analysis to improve the diagnosis of coronary artery disease, providing near-instant, accurate reports. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Primary Analysis Focus | Stress echocardiography analysis for coronary artery disease | Standard ECG analysis for hidden structural heart disease (heart failure, valve disease, pulmonary hypertension) |
Videos
Demos, reviews, and walkthroughs featuring EchoGo Pro and EchoNext.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
EchoGo Pro is designed for seamless integration with existing clinical workflows, connecting with PACS and EHR systems via DICOM and HL7, and can be triggered automatically after image acquisition. EchoNext is available through the OpenEvidence clinical decision support platform, allowing clinicians to submit ECG readings and receive structural heart disease predictions.
EchoGo Pro has demonstrated a specificity of 92.7% and a sensitivity of 84.4% for identifying severe coronary artery disease, with AI classification increasing sensitivity by 10% for clinicians. EchoNext correctly identified 77% of structural heart problems from ECGs alone in a validation study, outperforming cardiologists who achieved 64% accuracy without AI assistance.
EchoGo Pro aims to streamline workflows and provide near-instant reports, suggesting a reduced learning curve as it integrates into existing processes and provides automated analysis. EchoNext is designed to augment clinical decision-making as an early detection and triage tool, and its integration into a familiar platform like OpenEvidence may contribute to a smoother adoption for physicians.
Ultromics offers customer support for EchoGo Pro, and the system has been assessed at Mayo Clinic and is being rolled out in the UK National Health Service (NHS) as part of an award. Pathway Labs provides EchoNext through the OpenEvidence platform, which is an AI-based clinical decision support platform.
EchoGo Pro specializes in automating stress echocardiography analysis to diagnose coronary artery disease (CAD) and also offers modules for HFpEF and cardiac amyloidosis detection. EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, serving as an early detection and triage tool to identify patients who need an echocardiogram.
EchoGo Pro includes audit logging as a security feature. The EASE study protocol for EchoGo Pro also outlines plans to determine convergence and divergence between EchoGo Pro recommendations and cardiologists' interpretations, and how these link to outcomes, which implies a mechanism for tracking and evaluating the AI's impact. Information on specific audit-trail features for EchoNext is not detailed in the provided facts, but its role in clinical decision support suggests the importance of such capabilities for tracking its utility.
EchoGo Pro is a cloud-based solution designed for accessibility and scalability, with its infrastructure built to scale across echo labs, hospitals, and health systems, from single sites to enterprise-wide adoption. EchoNext is designed for broad access, from major hospitals to community practices, and its availability through a clinical decision support platform suggests a scalable deployment model.